(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback